NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

Benjamin T Dake, PhD

Ben has 15 years’ experience as an Entrepreneur, Scientist and Biotech Investor. He founded Aerovate to develop therapies with the potential to meaningfully change the treatment of rare diseases. Informed by his training in diseases of aberrant proliferation, he views PAH drug development through a unique lens focusing Aerovate on anti-proliferative therapies that directly address the root cause of disease.